Amiodarone Hcl

證據等級: L5 預測適應症: 0 個

目錄

  1. Amiodarone Hcl
  2. Amiodarone HCL: Antiarrhythmic Agent – Repurposing Assessment Incomplete
    1. One-Sentence Summary
    2. Quick Overview
    3. Why No Prediction is Currently Available
    4. UK Market Information
    5. Safety Considerations
    6. Conclusion and Next Steps
    7. Disclaimer
## 藥師評估報告

Amiodarone HCL: Antiarrhythmic Agent – Repurposing Assessment Incomplete

One-Sentence Summary

Amiodarone HCL is a well-established class III antiarrhythmic agent used in the management of life-threatening ventricular and supraventricular arrhythmias. The TxGNN model returned no predicted new indications for this drug in the current pipeline run, and the Evidence Pack contains critical data gaps that prevent a full repurposing evaluation from being completed at this stage. This report documents the current data status and outlines the remediation steps required before assessment can proceed.

Quick Overview

Item Content
Original Indication Not recorded in Evidence Pack
Predicted New Indication No predictions generated by TxGNN
TxGNN Prediction Score Not available
Evidence Level N/A – no predictions available
UK Market Status Not found in MHRA database (query returned 0 results)
Number of Marketing Authorisations 0 (likely a search artefact; see note below)
Recommended Decision Hold

Why No Prediction is Currently Available

The predicted_indications array in this Evidence Pack is empty, meaning the TxGNN pipeline did not surface any repurposing candidates for this compound at the time of data generation (2026-04-04).

Two likely causes should be investigated. First, the DrugBank ID for this compound was not resolved (drugbank_id: null), which would prevent the knowledge graph from anchoring the drug as a node and generating predictions. Second, the drug was queried under the salt form “AMIODARONE HCL” rather than the preferred INN “amiodarone”, which may have caused a mapping failure at the normalisation step.

Amiodarone has a complex, multi-target pharmacological profile — including Class III potassium channel blockade, sodium and calcium channel inhibition, and non-competitive beta-adrenergic antagonism — that theoretically supports repurposing interest. However, no mechanism-to-indication mapping has been produced by the current model run, and no evidence review can be conducted without a valid prediction to anchor it.

UK Market Information

The MHRA database lookup returned 0 marketing authorisations for the query term “AMIODARONE HCL”. This is almost certainly a search artefact. Amiodarone-containing products (e.g., Cordarone X) hold UK marketing authorisations and appear in the BNF under antiarrhythmics (BNF section 2.3.2). The salt suffix “HCL” in the query string is the most probable cause of the failed lookup.

No licence table can be generated from the current Evidence Pack. A corrected query is listed under Next Steps below.

Safety Considerations

Safety data was not retrieved in this Evidence Pack run. Amiodarone carries a well-documented and clinically significant adverse effect profile.

Before any further evaluation, the following steps are mandatory:

  • Review the full Summary of Product Characteristics (SmPC) for all UK-authorised amiodarone products via the MHRA Product Licence Search
  • Consult the BNF (British National Formulary), section 2.3.2 (Drugs for arrhythmias) for current prescribing guidance
  • Note that amiodarone carries black-box level warnings in multiple jurisdictions regarding pulmonary toxicity, hepatotoxicity, and thyroid dysfunction; these must be captured before any repurposing safety screen is run
  • Report suspected adverse reactions via the Yellow Card Scheme: https://yellowcard.mhra.gov.uk/

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is critically incomplete. No TxGNN predictions were generated, no MHRA licence data was retrieved, and both the mechanism of action and safety fields are unpopulated. A meaningful repurposing evaluation cannot be produced from the current data; proceeding without remediation would yield unreliable outputs.

To proceed, the following is needed:

  1. Re-run the MHRA database query using the INN amiodarone (without the “HCL” salt suffix) to retrieve correct UK marketing authorisation records
  2. Resolve the DrugBank ID — query the DrugBank API with the normalised INN to obtain drugbank_id, drug categories, and full MOA; this is the likely root cause of the empty prediction list
  3. Diagnose the TxGNN pipeline failure — confirm whether the drug was successfully mapped to a KG node; if drugbank_id was null at prediction time, re-run run_kg_prediction.py after resolving step 2
  4. Populate safety fields — extract key warnings, contraindications, and drug–drug interactions from the MHRA SmPC and BNF before any clinical use evaluation
  5. Re-run evidence collection (ClinicalTrials.gov, PubMed) against the top predicted indication once predictions are available

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.